RxDoctor Payments Data

Omar Gutierrez, MD

Family Medicine · Coushatta, LANPI 1396998977

Payments from drug & device makers

$1,820in general payments, 2019–2025

Across 40 payments — averaging $45.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$488
  • Amgen$391
  • Gilead$363
  • Astellas Pharma US Inc$139
  • AstraZeneca$125
  • Lilly USA, LLC$47
  • plus $267 from 10 others

What the payments were for

  • Food & beverage$1,820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,820 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$28,048
Medicare patients
123
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$100,697
EntrestoSacubitril/Valsartan127$75,680
MounjaroTirzepatide55$58,401
TrulicityDulaglutide44$48,539
EliquisApixaban81$43,154
Invega SustennaPaliperidone Palmitate12$41,831
FarxigaDapagliflozin Propanediol57$33,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,977
OzempicSemaglutide16$15,186
KerendiaFinerenone18$13,619
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen332$9,941
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen194$9,209
LantusInsulin Glargine,hum.Rec.Anlog15$5,064
SpsSodium Polystyrene Sulfon/Sorb12$4,998
VascepaIcosapent Ethyl14$4,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$47$106,94099 claims
Boehringer IngelheimJardiance$44$100,697121 claims
NovartisEntresto$14$75,680127 claims
PfizerEliquis$28$43,15481 claims
AstraZenecaFarxiga$125$33,28657 claims
GSKTrelegy Ellipta, Breo Ellipta$42$30,84944 claims
Novo NordiskOzempic$18$15,18616 claims
BayerKerendia$40$13,61918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Coushatta

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →